Sort
82,697 grants matching “vaccine development”
Reactions And Immunochemistry Of Carbohydrates
$1,125,125Pavol Kovac · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2010 · DK
Molecular Analysis of Tuberculosis Immunity
$1,125,036Albert Einstein Col Of Med Yeshiva Univ · P01 · FY2005 · AI
Mechanism of action and therapeutic utility of immunostimulatory CpG oligonucleo
$1,125,031Dennis Klinman · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Partnership to Optimize Equity in Maternal and Infant Health
$1,124,930Karen Fox · Delta Health Alliance, Inc. · OT2 · FY2023 · OD
Scanning B. pseudomallei proteome for vaccine antigens
$1,124,911Philip Louis Felgner · University Of California-Irvine · U01 · FY2006 · AI
An adjuvant that promotes TH1/TH17 and CD8 T cells in a tuberculosis vaccine
$1,124,887Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2016 · AI
WaNPRC MACACA NEMESTRINA SPF BREEDING COLONY
$1,124,742University Of Washington · U24 · FY2004 · RR
Characterization of the Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of a Candidate HIV Prevention Drug in Rhesus Macaques
$1,124,730Pal Ranajit · Advanced Bioscience Laboratories, Inc. · N01 · FY2019 · AI
Mechanism of action and therapeutic utility of immunostimulatory CpG oligonucleo
$1,124,689Dennis Klinman · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Replication Dynamics in Patients on Suppressive Antiretroviral Therapy
$1,124,659Frank Maldarelli · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Molecular Genetics Of Scrapie Pathogenesis
$1,124,443Suzette Alise Priola · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Mechanism of action and therapeutic utility of stimulatory CpG oligonucleotides
$1,124,257Dennis Klinman · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail
$1,124,215Robert F Garry · Tulane University Of Louisiana · R01 · FY2021 · AI
Development of a Safer Smallpox Vaccine
$1,124,042Bertram L. Jacobs · Arizona State University-Tempe Campus · U01 · FY2007 · AI
SPORE in Prostate Cancer
$1,124,001Michael M. Ittmann · Baylor College Of Medicine · P50 · FY2007 · CA
Class Switch Recombination in B Lymphocytes
$1,123,749Michel C Nussenzweig · Rockefeller University · R37 · FY2017 · AI
PA-50/PA-41 antitoxin antibody therapy for C. difficile infection
$1,123,669William C Olson · Progenics Pharmaceuticals, Inc. · R01 · FY2011 · AI
Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine
$1,123,350Jenny P.y. Ting · Univ Of North Carolina Chapel Hill · R01 · FY2021 · AI
Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses
$1,123,296Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Tickborne Disease: B cell epitope discovery and mechanisms of antibody Protection
$1,123,255Nicholas J Mantis · Nysdoh/Health Research, Inc. · N01 · FY2022 · AI
PREVALENCE AND DETERMINANTS OF ORAL HPV INFECTION IN THE US POPULATION
$1,123,239David Eric Symer · Ohio State University · R01 · FY2015 · DE
Computational models of naturally acquired immunity to falciparum malaria
$1,122,462Bryan R Greenhouse · University Of California, San Francisco · U01 · FY2021 · AI
Mechanisms of Effective Humoral Immune Responses to HIV-1
$1,122,303Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$1,122,303Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Dissecting the Conformational Flexibility of HIV-1 Envelope Glycoproteins
$1,122,273Alon Herschhorn · University Of Minnesota · R01 · FY2025 · AI